Biotechnological approach to fight H1N1 influenza

NewsGuard 100/100 Score

ETBOND TECHNOLOGY defines Biotechnology approach to fight H1N1 Influenza A (Swine Flu)

1. Plan for Morbidity Reduction: H1N1 Influenza A (Swine Flu and its symptoms) is spreading at a lightening speed globally. It is infecting millions of patients since first reported in April, 2009 in Mexico. Costly quarantine and control measures are in place to prevent the spread of the disease from patients to family and contacts in public places.

ETBOND TECHNOLOGY TM Plan: Since the much of spread occur through nasal route, ET 007 SWF is a Biotechnology drug that has been developed to reduce entry and fusion of Influenza A, 2009 (Swine Flu). The drug is assigned a Pre-IND number by FDA.

2. Plan for Mortality Reduction: The current method of medical management of H1N1 Influenza A (Swine Flu) in intensive care unit with the state of the art resources is costly and unmanageable. This is particularly obvious when the looming prospect of 1918 type of anticipated mortality in worst case scenario is considered.

ETBOND TECHNOLOGYTM Plan: Since much of the mortality is related to adverse interactions of virus with immune system that cause lung infection and death. ET 007 SWF is a biotechnology product advanced to Pre-IND stage with FDA. The drug will reduce the cost and management of H1N1 influenza A (Swine Flu) by providing antiviral and anti-inflammatory defenses in a safe way.

3. Plan for Vaccine Fears: Currently there is growing fear that preventive vaccine may not induce timely immune responses and it may be associated with severe adverse effects as seen in past.

ETBOND TECHNOLOGY TM Plan: The Company has advanced a biotechnology product to stimulate immune system while targeting virulence pathway with ET 007 SWF. This will shorten the duration needed for immune responses and will reduce adverse effects in the immediate post-vaccination time. FDA has assigned Pre-IND Number.

4. Plan for Global Consultancy: This is offered for H1N1 Influenza A (Swine Flu) through our web-site that provides online medical consultancy services to all players in life sciences after fee based registration.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study finds 4’-fluorouridine effective against avian influenza in vitro and in vivo